Info

🌱來自: renal-cell-carcinoma

Tyrosine kinase inhibitors-of-renal-cell-carcinoma

**1° endpoint(s) listed below include PFS &/or OS at interim analysis Class S/E: HTN, fatigue, diarrhea, stomatitis, nausea, hand-foot syn, skin/hair color changes ↓ LVEF, ↓ WBC, ↓ PLT, AST/ALT abnormalities, TFT abnormalities Axitinib (Lancet 2011;378:1931) vs. sorafenib: PFS: 6.7 mos vs. 4.7 mos (HR: 0.665, P <0.0001) Cabozantinib (NEJM 2015;373:1814) vs. everolimus: PFS 7.4 mos vs. 3.8 mos (HR: 0.58, P <0.001) Pazopanib (JCO 2010;28:1061) vs. placebo: PFS: 9.2 mos vs. 4.2 mos (HR: 0.46, P <0.0001) Sorafenib (NEJM 2007; 357:203) vs. placebo: OS: 78% vs. 73% (HR for death: 0.72, P = 0.02) Sunitinib (NEJM 2007;356:115) vs. IFNα: PFS 11 mos vs. 5 mos (HR: 0.42, P <0.001)

Siblings

• Epidemiology-of-renal-cell-carcinoma
• Histology and molecular biology-of-renal-cell-carcinoma
• Hereditary RCC and germline testing-of-renal-cell-carcinoma
• Clinical presentation-of-renal-cell-carcinoma
• Staging (TNM classification) and prognosis-of-renal-cell-carcinoma
• Treatment principles-of-renal-cell-carcinoma
• Systemic therapy for metastatic clear cell RCC
• Second-line therapies-of-renal-cell-carcinoma
• Combined-modality therapies-of-renal-cell-carcinoma
• Tyrosine kinase inhibitors-of-renal-cell-carcinoma
• Immunotherapies-of-renal-cell-carcinoma
• mTOR inhibitors-of-renal-cell-carcinoma
• Non-clear cell histology-of-renal-cell-carcinoma